A new trading day began on Friday, with Novavax, Inc (NASDAQ: NVAX) stock price up 7.71% from the previous day of trading, before settling in for the closing price of $8.30. NVAX’s price has ranged from $3.53 to $23.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 513.29%. Meanwhile, its annual earnings per share averaged 73.63%. With a float of $153.02 million, this company’s outstanding shares have now reached $160.15 million.
Let’s determine the extent of company efficiency that accounts for 1543 employees. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc is 4.47%, while institutional ownership is 58.98%. The most recent insider transaction that took place on Sep 18 ’24, was worth 95,331. Before that another transaction happened on Jun 21 ’24, when Company’s Director sold 7,500 for $14.09, making the entire transaction worth $105,675. This insider now owns 61,760 shares in total.
Novavax, Inc (NVAX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 73.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Here are Novavax, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach 0.10 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Looking closely at Novavax, Inc (NASDAQ: NVAX), its last 5-days average volume was 4.26 million, which is a drop from its year-to-date volume of 9.46 million. As of the previous 9 days, the stock’s Stochastic %D was 33.22%. Additionally, its Average True Range was 0.64.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 19.36%, which indicates a significant decrease from 72.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.65% in the past 14 days, which was lower than the 97.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.08, while its 200-day Moving Average is $10.33. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $9.53. Second resistance stands at $10.11. The third major resistance level sits at $10.68. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $7.81. Now, if the price goes above the second support level, the third support stands at $7.23.
Novavax, Inc (NASDAQ: NVAX) Key Stats
With a market capitalization of 1.54 billion, the company has a total of 160,185K Shares Outstanding. Currently, annual sales are 983,710 K while annual income is -545,060 K. The company’s previous quarter sales were 84,510 K while its latest quarter income was -121,300 K.
